PSICOFARMACOLOGIA ON-LINE

Schizophrenia-Psychotic Disorders & Antipsychotics

(Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

GRATIS = Texto gratuito en algunos países de la región iberoamericana (algunos artículos requieren ir a la tabla de contenidos del número actual de la revista)

3 - IQ tests as aids to diagnosis and management in early schizophrenia

Phil Harrison-Read

Advances in Psychiatric Treatment (2008) 14: 235-240

3! - Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study

James J. Newham, Simon H. Thomas, Karine MacRitchie, Patricia R. McElhatton, R. Hamish McAllister-Williams

The British Journal of Psychiatry (2008) 192: 333-337

GRATIS 3 - Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

Gunnar Morken, Jan H Widen and Rolf W Grawe

BMC Psychiatry 2008, 8:32

3 - The possible involvement of metabotropic glutamate receptors in schizophrenia

Amir Krivoy^a^,^,, Tsvi Fischel^a^,^b and Abraham Weizman^a^,^b^,^c

European Neuropsychopharmacology. Volume 18, Issue 6, June 2008, Pages 395-405

3 - Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT_1A receptors

Hiroko Hagiwara^a^,^b, Yuko Fujita^a, Tamaki Ishima^a, Shinsui Kunitachi^a, Yukihiko Shirayama^b, Masaomi Iyo^b and Kenji Hashimoto^a^,^,

European Neuropsychopharmacology. Volume 18, Issue 6, June 2008, Pages 448-454

5 - Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial

Matthew J. Byerly^a^,^,, Paul A. Nakonezny^b and A. John Rush^c

Psychiatry Research. Volume 159, Issues 1-2, 30 May 2008, Pages 115-120

5< - Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study

Trino Baptista^a^,^,, Euderruh Uzcátegui^b, Nairy Rangel^c, Yamily El Fakih^b, Tatiana Galeazzi^d, Serge Beaulieu^e and Enma Araujo de Baptista

Psychiatry Research. Volume 159, Issues 1-2, 30 May 2008, Pages 250-253

3 - Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex

Tomohiro Abekawa^,^a^,, Koki Ito^a, Shin Nakagawa^a, Yasuya Nakato^a and Tsukasa Koyama

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 84-94

3! - An increased risk of stroke among young schizophrenia patients

Herng-Ching Lin^a, Fei-Hsiu Hsiao^b, Stefani Pfeiffer^c, Yi-Ting Hwang^d and Hsin-Chien Lee^e^,^f^,^,

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 234-241

3! - Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

Julie Kreyenbuhl^a^,^b^,^,, Deborah R. Medoff^a^,^b, Stephen L. Seliger^c and Lisa B. Dixon^a^,^b

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 256-265

5 - Metabolic syndrome in first episode schizophrenia — A randomized double-blind controlled, short-term prospective study

Sahoo Saddichha^a^,^,, Narayana Manjunatha^b, Shahul Ameen^c and Sayeed Akhtar

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 266-272

4 - Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

Jonathan M. Meyer^a^,^b^,^,, Vicki G. Davis^c^,, Donald C. Goff^d^,^e^,, Joseph P. McEvoy^f^,^g^,, Henry A. Nasrallah^h^,^,, Sonia M. Davisⁱ^,, Robert A. Rosenheck^j^,^k^,^l^,, Gail L. Daumit^m^,, John Hsiaoⁿ^,, Marvin S. Swartz^o^,, T. Scott Stroup^p^,and Jeffrey A. Lieberman

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 273-286

3! - Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects

Karen A. Graham^a^,^,, Hyunsoon Cho^b^,, Kimberly A. Brownley^a^,and Joyce B. Harp

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 287-294

3 - Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Marc De Hert^a^,^,, Vincent Schreurs^a, Kim Sweers^a, Dominique Van Eyck^a, Linda Hanssens^b, Sebastjan Šinko^c, Martien Wampers^a, Andre Scheen^d, Joseph Peuskens^a and Ruud van Winkel^a^,^e

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 295-303

3 - Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia

Susan dosReis^a^,^b^,^,, Elizabeth Johnson^c^,, Donald Steinwachs^b^,, Charles Rohde^c^,, Elizabeth A. Skinner^b^,, Maureen Fahey^b^,and Anthony F. Lehman

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 304-311

4 - Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study

Stefan Leucht^a^,^b^,^,, Syed Ali Raza Shamsi^a^,^b^,¹, Raymonde Busch^c, Werner Kissling^a^,¹ and John M. Kane

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 312-319

3 - Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300

Yuko Higuchi^a, Tomiki Sumiyoshi^a^,^b^,^,, Yasuhiro Kawasaki^a^,^b, Mie Matsui^b^,^c, Hirofumi Arai^b^,^d and Masayoshi Kurachi^b^,^d

Schizophrenia Research. Volume 101, Issues 1-3, April 2008, Pages 320-330

3 - Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

Chun-Hsin Chen^a^,^b, Chih-Chiang Chiu^a^,^c^,^d, Ming-Chyi Huang^a^,^c, Tzu-Hua Wu^e, Hui-Ching Liu^f and Mong-Liang Lu

Progress in Neuro-Psychopharmacology and Biological Psychiatry. Volume 32, Issue 4, 15 May 2008, Pages 925-931

3 - Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients

V. Molina^a^,^,, P. Tamayo^b, C. Montes^c, A. De Luxán^d, C. Martin^a, N. Rivas^e, C. Sancho^f and A. Domínguez-Gil

Progress in Neuro-Psychopharmacology and Biological Psychiatry. Volume 32, Issue 4, 15 May 2008, Pages 948-954

3 - Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia

Jin Hun Kim^a^,^b^,^,^,, Daeho Kim^c and Stephen R. Marder

Progress in Neuro-Psychopharmacology and Biological Psychiatry. Volume 32, Issue 4, 15 May 2008, Pages 984-988

GRATIS 3 - Características de los pacientes que desarrollaron el Síndrome Neuroléptico

Maligno en un Hospital Psiquiátrico

Francisco Franco López Salazar, Nancy Espinosa Rodríguez

Alcmeon, Año XVII, Vol. 14, Nº 3, marzo de 2008, págs. 55 a 65

3 - Elevated serum creatine kinase levels in psychiatric practice: differential diagnosis and clinical significance: A brief, practical guideline for clinicians

Viktor Voros; Peter Osvath; Sandor Fekete; Tamas Tenyi

International Journal of Psychiatry in Clinical Practice, Volume 12, Issue 2 2008, pages 147 - 150

GRATIS 3 - Structural neuroimaging in first-episode psychosis

National Institute for Health and Clinical Excellence (NICE)

London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Feb. 24 (Technology appraisal guidance; no. 136)

4 - Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

Herbert Y. Meltzer, William V. Bobo, Isaac F. Nuamah, Rosanne Lane, David Hough, Michelle Kramer, and Marielle Eerdekens

J Clin Psychiatry May 6, 2008: e1-e13

3 - Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression

Mei Han^a^,^b, Chao Deng^a^,^b, Thomas H.J. Burne^c^,^d, Kelly A. Newell^a^,^b and Xu-Feng Huang

Psychoneuroendocrinology. Volume 33, Issue 5, June 2008, Pages 569-580

3! - Schizophrenia - Neurodevelopmental Disorder or Degenerative Brain Process?

G. Gross, G. Huber

Fortschr Neurol Psychiatr 2008; 76: S57-S62

5< - A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia

Tony P. George^a^,^b^,^c^,^,, Jennifer C. Vessicchio^b^,^c, Kristi A. Sacco^b^,^c, Andrea H. Weinberger^b^,^c, Melissa M. Dudas^b, Taryn M. Allen^b, Cerissa L. Creeden^b, Marc N. Potenza^c, Alan Feingold^e and Peter I. Jatlow^d

Biological Psychiatry. Volume 63, Issue 11, 1 June 2008, Pages 1092-1096

3 - A Randomized, Crossover Comparison of Herbal Medicine and Bromocriptine Against Risperidone-Induced Hyperprolactinemia in Patients With Schizophrenia

Yuan, Hai-Ning; Wang, Chuan-Yue; Sze, Cho Wing; Tong, Yao; Tan, Qing-Rong; Feng, Xiu-Jie; Liu, Rui-Mei; Zhang, Ji-Zhi; Zhang, Yan-Bo; Zhang, Zhang-Jin

Journal of Clinical Psychopharmacology. 28(3):264-370, June 2008

3 - A Pharmacoeconomic Analysis of Atypical Antipsychotics and Haloperidol in First-Episode Schizophrenic Patients in Taiwan

Gau, Susan Shur-Fen; Chung, Ching-Hu; Gau, Churn-Shiouh

Journal of Clinical Psychopharmacology. 28(3):271-278, June 2008

3! - Maternal Use of Antipsychotics in Early Pregnancy and Delivery Outcome

Reis, Margareta; Kallen, Bengt

Journal of Clinical Psychopharmacology. 28(3):279-288, June 2008

3 - Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment

Perez-Iglesias, Rocio; Vazquez-Barquero, Jose Luis; Amado, Jose Antonio; Berja, Ana; Garcia-Unzueta, Maria Teresa; Pelayo-Teran, Jose Maria; Carrasco-Marin, Eugenio; Mata, Ignacio; Crespo-Facorro, Benedicto

Journal of Clinical Psychopharmacology. 28(3):289-295, June 2008

GRATIS (previo registro) 5 - Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Walter Deberdt, Ilya Lipkovich, Alexandra N Heinloth, Lin Liu, Sara Kollack-Walker, Sara E Edwards, Vicki Poole Hoffmann, Thomas A Hardy

Therapeutics and Clinical Risk Management. ON-LINE EARLY. May 2008

3 - Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia

R C Smith, R H Segman, T Golcer-Dubner, V Pavlov and B Lerer

The Pharmacogenomics Journal (2008) 8, 228–236

3 - Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia

Edoardo Spina & Rocco Zoccali

Expert Opinion on Drug Metabolism & Toxicology. May 2008, Vol. 4, No. 5, Pages 629-638

3! - Estimating the Size of the Effects of Co-Medications on Plasma Clozapine Concentrations using a Model that Controls for Clozapine Doses and Confounding Variables

F. J. Diaz, V. Santoro, E. Spina, M. Cogollo, T. E. Rivera, S. Botts, J. de Leon

Pharmacopsychiatry 2008; 41: 81-91

3 - Effects of Olanzapine on Slow Wave Sleep, Sleep Spindles and Sleep-Related Memory Consolidation in Schizophrenia

R. Göder, G. Fritzer, B. Gottwald, B. Lippmann, M. Seeck-Hirschner, I. Serafin, J. B. Aldenhoff

Pharmacopsychiatry 2008; 41: 92-99

3 - Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene

A. Méary, G. Brousse, S. Jamain, A. Schmitt, A. Szöke, F. Schürhoff, G. Gavaudan, C. Lancon, I. Macquin-Mavier, M. Leboyer, P.M. Llorca

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. Volume 147B, Issue 4, Pages 491 - 494

3! - Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia

Robin Hieber, Timothy Dellenbaugh, Leigh Anne Nelson

The Annals of Pharmacotherapy: Vol. 42, No. 6, pp. 841-846

3 - Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain

Baptista, Trino; ElFakih, Yamily; Uzcategui, Euderruh; Sandia, Ignacio; Talamo, Eduardo; Araujo de Baptista, Enma; Beaulieu, Serge

CNS Drugs. 22(6):477-495, 2008

3! - The Effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory study

Manuel Morrens ¹^,²^,^,, Wouter Hulstijn and Bernard Sabbe

Clinical Therapeutics. Volume 30, Issue 4, April 2008, Pages 684-692

3 - Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

David H. Adams, Sandra Close, Mark Farmen, AnnCatherine M. Downing, Alan Breier, John P. Houston

Human Psychopharmacology: Clinical and Experimental. Volume 23 Issue 4, Pages 267 - 274

3 - Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain

Jamie Karagianis, Vicki Poole Hoffmann, Belen Arranz, Tamás Treuer, Gerald A. Maguire, Lieuwe de Haan, Bharat Chawla

Human Psychopharmacology: Clinical and Experimental. Volume 23 Issue 4, Pages 275 - 281

3! - Early detection and intervention of psychosis. A review

Raimo K. R. Salokangas; Thomas H. McGlashan

Nordic Journal of Psychiatry, Volume 62, Issue 2 2008 , pages 92 - 105

3 - Hypofrontality in subjects at high genetic risk of schizophrenia with depressive symptoms

H.C. Whalley^,^a^,, L. Mowatt^a, A.C. Stanfield^a, J. Hall^a, E.C. Johnstone^a, S.M. Lawrie^a and A.M. McIntosh

Journal of Affective Disorders. Volume 109, Issues 1-2, July 2008, Pages 99-106

3 - The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory study

Manuel Morrens ¹^,²^,^,, Wouter Hulstijn and Bernard Sabbe

Clinical Therapeutics. Volume 30, Issue 4, April 2008, Pages 684-692

3 - Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex

Se Hyun Kim, Myoung Suk Seo, Won Je Jeon, Hyun-Sook Yu, Hong Geun Park, Gyung-Ah Jung, Hee Young Lee, Ung Gu Kang and Yong Sik Kim

The International Journal of Neuropsychopharmacology (2008), 11:509-517

3 - Chronic antipsychotic drug administration alters the expression of neuregulin 1β, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus

Xiao-Dong Wang, Yun-Ai Su, Chun-Mei Guo, Yang Yang and Tian-Mei Si

The International Journal of Neuropsychopharmacology (2008), 11:553-561

3 - Olanzapine counteracts stress-induced anxiety-like behavior in rats

Federica Locchi^a, Rossella Dall’Olio^a, Ottavio Gandolfi^a and Roberto Rimondini

Neuroscience Letters. Volume 438, Issue 2, 20 June 2008, Pages 146-149

3! - Twins discordant for schizophrenia: psychopathology of the non-schizophrenic co-twins

S. V. Argyropoulos, S. Landau, S. Kalidindi, T. Toulopoulou, D. J. Castle, R. M. Murray, M. M. Picchioni
Acta Psychiatrica Scandinavica. OnlineEarly; May 2008

GRATIS 3 - Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.

Dalila Benmessaoud, Nora Hamdani, Claudette Boni, Nicolas Ramoz, Michel Hamon, Farid Kacha and Philip Gorwood

BMC Psychiatry 2008, 8:40

5 - Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine

Deanna L. Kelly; Robert R. Conley; Raymond C. Love; John A. Morrison; Robert P. Mcmahon

Annals of Clinical Psychiatry, Volume 20, Issue 2 May 2008, pages 71 - 78

3 - Repeated low dose of phencyclidine administration impairs spatial learning in mice: Blockade by clozapine but not by haloperidol

Simret Beraki¹^,^a, Alexander Kuzmin¹^,^a, Fadao Tai^a and Sven Ove Ögren

European Neuropsychopharmacology. Volume 18, Issue 7, July 2008, Pages 486-497

3! - Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum

Fabrizio Gardoni^a, Angelisa Frasca^a, Elisa Zianni^a, Marco A. Riva^a, Monica Di Luca^a and Fabio Fumagalli

European Neuropsychopharmacology. Volume 18, Issue 7, July 2008, Pages 531-534

3 - Clinical Characterization of Late- and Very Late-Onset First Psychotic Episode in Psychiatric Inpatients

Caroline Girard, and Martine Simard

Am J Geriatr Psychiatry 16:478-487, June 2008

5 - Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers

Julia Sacher, Nilufar Mossaheb, Christoph Spindelegger, Nikolas Klein, Thomas Geiss-Granadia, Robert Sauermann, Edith Lackner, Christian Joukhadar, Markus Müller and Siegfried Kasper

Neuropsychopharmacology (2008) 33, 1633–1641

3 - In Vitro and In Vivo Characterization of the Non-peptide NK₃ Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia

Lee A Dawson, Katherine J Cato, Claire Scott, Jeannette M Watson, Martyn D Wood, Richard Foxton, Raúl de la Flor, Gareth A Jones, James NC Kew, Jane E Cluderay, Eric Southam, Graham S Murkitt, Jane Gartlon, Darrel J Pemberton, Declan NC Jones, Ceri H Davies and Jim Hagan

Neuropsychopharmacology (2008) 33, 1642–1652

3 - Differential Effects of Antipsychotic and Glutamatergic Agents on the phMRI Response to Phencyclidine

Alessandro Gozzi, Charles H Large, Adam Schwarz, Simone Bertani, Valerio Crestan and Angelo Bifone

Neuropsychopharmacology (2008) 33, 1690–1703

3< - Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia

Julie Kreyenbuhl, Steven C. Marcus, Joyce C. West, Joshua Wilk, and Mark Olfson

Focus 6:212-220, Spring 2008

3! - Mortality and Medical Comorbidity Among Patients With Serious Mental Illness

Brian J. Miller, C. Bayard Paschall III, and Dale P. Svendsen

Focus 6:239-245, Spring 2008

GRATIS 3! - Factors in the Etiology of Schizophrenia: Genes, Parental Age, and Environment

Mark G. A. Opler, Mary C. Perrin, Karine Kleinhaus, and Dolores Malaspina

Primary Psychiatry. 2008;15(6):37-45

GRATIS 3 - Cannabis as a Risk Factor for Psychosis in Vulnerable Teens: Implications for Treatment

Lauren L. Bodkin, Anjuli Singh, and Cheryl Corcoran

Primary Psychiatry. 2008;15(6):51-57

GRATIS 3 - Is Recovery from Schizophrenia Possible? An Overview of Concepts, Evidence, and Clinical Implications

Paul H. Lysaker, and Kelly D. Buck

Primary Psychiatry. 2008;15(6):60-65

Regresar a RESÚMENES MAYO 2008

.

© 1999-2008 Jorge M Tamayo, MD, BMSS
Creada en Enero 1999

Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA.